person · Reporting owner

Meeker David P

Disclosed activity across 6 companies

Tapewire entity: 36265
SEC CIK: 0001385155

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Kardigan, Inc.KARD · Entity 4569	Director	June 17, 2026	June 22, 2026
Pharvaris N.V.PHVS · Entity 4374	Director	March 18, 2026	March 18, 2026
RHYTHM PHARMACEUTICALS, INC.RYTM · Entity 3693	Director · President and CEO	September 14, 2026	September 14, 2026
TURMERIC ACQUISITION CORP.TMPM · Entity 139875	Director	October 15, 2020	October 15, 2020
Trevi Therapeutics, Inc.TRVI · Entity 4387	Director	June 03, 2026	June 04, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Kardigan, Inc.

Report date June 17, 2026 · Filed June 22, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	20,706	Reported balance After 2026-06-17 transaction · row 1 1 source row Row 1 · 2026-06-17 · Grant · Acquired 20,706 · Balance 20,706 F1: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on June 17, 2028, subject to the Reporting Person's continuous service as of the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on June 17, 2028, subject to the Reporting Person's continuous service as of the applicable vesting date.

Pharvaris N.V.

Report date March 18, 2026 · Filed March 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	65,167	Reported balance Holding disclosure · report date 2026-03-18 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 65,167 F1: Includes restricted stock units previously granted under the Company's equity plan that remain outstanding as of March 18, 2026. The awards settle in shares of common stock and are reported in Table I as non-derivative securities. Vesting occurs as follows: -5,500 RSUs from an award granted March 3, 2026 of which 100% will vest March 3, 2027.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.00 · Expires 2036-03-03	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-03-18 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance Not disclosed F2: 100% of the option vest on the 12-month anniversary.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.05 · Expires 2035-03-12	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-03-18 · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · Balance Not disclosed F2: 100% of the option vest on the 12-month anniversary.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.31 · Expires 2034-04-11	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-03-18 · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · Balance Not disclosed F2: 100% of the option vest on the 12-month anniversary.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.05 · Expires 2033-04-06	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-03-18 · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · Balance Not disclosed F3: 25% of the option vested on April 6, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.14 · Expires 2032-04-01	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-03-18 · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · Balance Not disclosed F4: 25% of the option vested on April 1, 2023 with the remaining shares vesting in 1/48 monthly installments thereafter.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.89 · Expires 2031-01-01	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-03-18 · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · Balance Not disclosed F5: 25% of the option vested on January 1, 2022 with the remaining shares vesting in 1/48 monthly installments thereafter.

Filing footnotes · ownership attribution and instrument terms

F1: Includes restricted stock units previously granted under the Company's equity plan that remain outstanding as of March 18, 2026. The awards settle in shares of common stock and are reported in Table I as non-derivative securities. Vesting occurs as follows: -5,500 RSUs from an award granted March 3, 2026 of which 100% will vest March 3, 2027.

F2: 100% of the option vest on the 12-month anniversary.

F3: 25% of the option vested on April 6, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter.

F4: 25% of the option vested on April 1, 2023 with the remaining shares vesting in 1/48 monthly installments thereafter.

F5: 25% of the option vested on January 1, 2022 with the remaining shares vesting in 1/48 monthly installments thereafter.

RHYTHM PHARMACEUTICALS, INC.

Report date September 14, 2026 · Filed September 14, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	289,258	Reported balance After 2026-09-14 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-09-14 · Exercise / conversion · Acquired 50,000 · Balance 289,258 F1: The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2026. F2: Includes 242 shares acquired under the Rhythm Pharmaceuticals, Inc. employee stock purchase plan on 2-28-2026.
Common StockSEC Table I · non-derivative	Direct	282,819	Reported balance After 2026-09-14 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2026-09-14 · Sale · Disposed 6,439 · Balance 282,819 F1: The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2026. F3: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $100.96 to $101.95 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Common StockSEC Table I · non-derivative	Direct	252,073	Reported balance After 2026-09-14 transaction · row 3 Account or security details depend on footnotes; rows are not merged. 1 source row Row 3 · 2026-09-14 · Sale · Disposed 30,746 · Balance 252,073 F1: The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2026. F4: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $101.96 to $102.94 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Common StockSEC Table I · non-derivative	Direct	243,375	Reported balance After 2026-09-14 transaction · row 4 Account or security details depend on footnotes; rows are not merged. 1 source row Row 4 · 2026-09-14 · Sale · Disposed 8,698 · Balance 243,375 F1: The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2026. F5: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $102.97 to $103.96 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Common StockSEC Table I · non-derivative	Direct	241,558	Reported balance After 2026-09-14 transaction · row 5 Account or security details depend on footnotes; rows are not merged. 1 source row Row 5 · 2026-09-14 · Sale · Disposed 1,817 · Balance 241,558 F1: The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2026. F6: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $103.97 to $104.94 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Common StockSEC Table I · non-derivative	Direct	239,258	Reported balance After 2026-09-14 transaction · row 6 Account or security details depend on footnotes; rows are not merged. 1 source row Row 6 · 2026-09-14 · Sale · Disposed 2,300 · Balance 239,258 F1: The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2026. F7: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $105.00 to $105.31 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.05 · Expires 2027-02-07	Direct	15,431	Reported balance After 2026-09-14 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-09-14 · Exercise / conversion · Disposed 50,000 · Balance 15,431 F8: The stock options were granted on February 8, 2017 and vested and became exercisable in three equal annual installments measured from January 6, 2017.

Filing footnotes · ownership attribution and instrument terms

F1: The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2026.

F2: Includes 242 shares acquired under the Rhythm Pharmaceuticals, Inc. employee stock purchase plan on 2-28-2026.

F3: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $100.96 to $101.95 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $101.96 to $102.94 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F5: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $102.97 to $103.96 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F6: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $103.97 to $104.94 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F7: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $105.00 to $105.31 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F8: The stock options were granted on February 8, 2017 and vested and became exercisable in three equal annual installments measured from January 6, 2017.

TURMERIC ACQUISITION CORP.

Report date October 15, 2020 · Filed October 15, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class B Ordinary Shares, par value $0.0001SEC Table I · non-derivative	Direct	25,000	Reported balance Holding disclosure · report date 2020-10-15 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 25,000
Class B Ordinary Shares, par value $0.0001SEC Table II · derivative / convertible security	Direct	Not disclosed	Reported balance Holding disclosure · report date 2020-10-15 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance Not disclosed F1: As described in the issuer's registration statement on Form S-1 (File No. 333-249099) under the heading "Description of Securities--Founder Shares", the Class B ordinary shares, par value $0.0001 per share, will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment for share splits, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: As described in the issuer's registration statement on Form S-1 (File No. 333-249099) under the heading "Description of Securities--Founder Shares", the Class B ordinary shares, par value $0.0001 per share, will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment for share splits, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date.

Trevi Therapeutics, Inc.

Report date June 03, 2026 · Filed June 04, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Nonstatutory Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.45 · Expires 2036-06-02	Direct	35,000	Reported balance After 2026-06-03 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-03 · Grant · Acquired 35,000 · Balance 35,000 F1: This option was granted on June 3, 2026. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: This option was granted on June 3, 2026. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

MyoKardia, Inc.

Report date November 17, 2020 · Filed November 20, 2020

Section 16 reporting ended · disclosed 2020-11-20. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2020-11-17 transaction · row 1 1 source row Row 1 · 2020-11-17 · Other · Disposed 4,100 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the Offer Price.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.55	Direct	Reported balance After 2020-11-17 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-11-17 · Disposition to issuer · Disposed 22,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.00	Direct	Reported balance After 2020-11-17 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-11-17 · Disposition to issuer · Disposed 11,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.85	Direct	Reported balance After 2020-11-17 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-11-17 · Disposition to issuer · Disposed 11,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.77	Direct	Reported balance After 2020-11-17 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-11-17 · Disposition to issuer · Disposed 6,600 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $100.27	Direct	Reported balance After 2020-11-17 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-11-17 · Disposition to issuer · Disposed 3,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.

F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the Offer Price.

F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 14, 2026 Filed Sep 14, 2026 23:37 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	50,000	$0.00 Strike: $6.05	$0.00	Disclosure SEC source: 0001649904-26-000026 · form4.xml · derivative · entry 7 Meeker David P · CIK 0001385155 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,431 Underlying: Common Stock · 50,000 shares Expires 2027-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The stock options were granted on February 8, 2017 and vested and became exercisable in three equal annual installments measured from January 6, 2017. Read SEC document
September 14, 2026 Filed Sep 14, 2026 23:37 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	SaleCommon Stock	2,300	$105.19	$241,937.00	Disclosure SEC source: 0001649904-26-000026 · form4.xml · nonDerivative · entry 6 Meeker David P · CIK 0001385155 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 239,258 F1 · kind: The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2026. F7 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $105.00 to $105.31 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
September 14, 2026 Filed Sep 14, 2026 23:37 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	SaleCommon Stock	1,817	$104.55	$189,964.99	Disclosure SEC source: 0001649904-26-000026 · form4.xml · nonDerivative · entry 5 Meeker David P · CIK 0001385155 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 241,558 F1 · kind: The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2026. F6 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $103.97 to $104.94 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
September 14, 2026 Filed Sep 14, 2026 23:37 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	SaleCommon Stock	8,698	$103.43	$899,634.14	Disclosure SEC source: 0001649904-26-000026 · form4.xml · nonDerivative · entry 4 Meeker David P · CIK 0001385155 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 243,375 F1 · kind: The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2026. F5 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $102.97 to $103.96 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
September 14, 2026 Filed Sep 14, 2026 23:37 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	SaleCommon Stock	30,746	$102.35	$3,146,760.86	Disclosure SEC source: 0001649904-26-000026 · form4.xml · nonDerivative · entry 3 Meeker David P · CIK 0001385155 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 252,073 F1 · kind: The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2026. F4 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $101.96 to $102.94 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
September 14, 2026 Filed Sep 14, 2026 23:37 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	SaleCommon Stock	6,439	$101.75	$655,145.07	Disclosure SEC source: 0001649904-26-000026 · form4.xml · nonDerivative · entry 2 Meeker David P · CIK 0001385155 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 282,819 F1 · kind: The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2026. F3 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $100.96 to $101.95 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
September 14, 2026 Filed Sep 14, 2026 23:37 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	Exercise / conversionCommon Stock	50,000	$6.05	$302,500.00	Disclosure SEC source: 0001649904-26-000026 · form4.xml · nonDerivative · entry 1 Meeker David P · CIK 0001385155 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 289,258 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2026. F2 · balance_after: Includes 242 shares acquired under the Rhythm Pharmaceuticals, Inc. employee stock purchase plan on 2-28-2026. Read SEC document
June 17, 2026 Filed Jun 22, 2026 23:28 UTC	Kardigan, Inc. KARD · Entity 4569	GrantCommon Stock	20,706	$0.00	$0.00	Disclosure SEC source: 0001193125-26-277950 · ownership.xml · nonDerivative · entry 1 Meeker David P · CIK 0001385155 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,706 F1 · kind: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on June 17, 2028, subject to the Reporting Person's continuous service as of the applicable vesting date. Read SEC document
June 03, 2026 Filed Jun 4, 2026 20:05 UTC	Trevi Therapeutics, Inc. TRVI · Entity 4387	GrantNonstatutory Stock Option (right to buy) · Derivative	35,000	$0.00 Strike: $13.45	$0.00	Disclosure SEC source: 0001193125-26-257373 · ownership.xml · derivative · entry 1 Meeker David P · CIK 0001385155 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2036-06-02 F1 · derivative.exercise_date: This option was granted on June 3, 2026. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer. Read SEC document
February 11, 2026 Filed Feb 13, 2026 22:52 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	GrantStock Options (Right to Buy) · Derivative	107,850	$0.00 Strike: $98.47	$0.00	Disclosure SEC source: 0001104659-26-015403 · tm266366-6_4seq1.xml · derivative · entry 2 Meeker David P · CIK 0001385155 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,850 Underlying: Common Stock · 107,850 shares Expires 2036-02-10 F3 · derivative.exercise_date: The stock options were granted on February 11, 2026. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document
February 11, 2026 Filed Feb 13, 2026 22:52 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	GrantRestricted Stock Units · Derivative	71,900	$0.00	$0.00	Disclosure SEC source: 0001104659-26-015403 · tm266366-6_4seq1.xml · derivative · entry 1 Meeker David P · CIK 0001385155 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,900 Underlying: Common Stock · 71,900 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 1, 2027, February 1, 2028, February 1, 2029 and February 1, 2030. The restricted stock units have no expiration date. F2 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 1, 2027, February 1, 2028, February 1, 2029 and February 1, 2030. The restricted stock units have no expiration date. Read SEC document
February 01, 2026 Filed Feb 3, 2026 21:34 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	Exercise / conversionRestricted Stock Units · Derivative	33,338	$0.00	$0.00	Disclosure SEC source: 0001104659-26-009768 · tm264963-6_4seq1.xml · derivative · entry 5 Meeker David P · CIK 0001385155 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,012 Underlying: Common Stock · 33,338 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F5 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 1, 2026, February 1, 2027, February 1, 2028 and February 1, 2029. The restricted stock units have no expiration date. F5 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 1, 2026, February 1, 2027, February 1, 2028 and February 1, 2029. The restricted stock units have no expiration date. Read SEC document
February 01, 2026 Filed Feb 3, 2026 21:34 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	Exercise / conversionRestricted Stock Units · Derivative	21,250	$0.00	$0.00	Disclosure SEC source: 0001104659-26-009768 · tm264963-6_4seq1.xml · derivative · entry 4 Meeker David P · CIK 0001385155 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,500 Underlying: Common Stock · 21,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 1, 2026, February 1, 2027 and February 1, 2028. The restricted stock units have no expiration date. F4 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 1, 2026, February 1, 2027 and February 1, 2028. The restricted stock units have no expiration date. Read SEC document
February 01, 2026 Filed Feb 3, 2026 21:34 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	Exercise / conversionRestricted Stock Units · Derivative	14,125	$0.00	$0.00	Disclosure SEC source: 0001104659-26-009768 · tm264963-6_4seq1.xml · derivative · entry 3 Meeker David P · CIK 0001385155 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,125 Underlying: Common Stock · 14,125 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date. Read SEC document
February 01, 2026 Filed Feb 3, 2026 21:34 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	Tax withholdingCommon Stock	31,522	$108.99	$3,435,582.78	Disclosure SEC source: 0001104659-26-009768 · tm264963-6_4seq1.xml · nonDerivative · entry 2 Meeker David P · CIK 0001385155 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 239,016 F2 · kind: These shares were withheld for payment of the withholding taxes upon the vesting of the restricted stock units reported herein. Read SEC document
February 01, 2026 Filed Feb 3, 2026 21:34 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	Exercise / conversionCommon Stock	68,713	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-26-009768 · tm264963-6_4seq1.xml · nonDerivative · entry 1 Meeker David P · CIK 0001385155 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 270,538 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document
June 11, 2025 Filed Jun 13, 2025 20:00 UTC	Trevi Therapeutics, Inc. TRVI · Entity 4387	GrantNonstatutory Stock Option (right to buy) · Derivative	45,000	$0.00 Strike: $6.25	$0.00	Disclosure SEC source: 0000950170-25-086109 · ownership.xml · derivative · entry 1 Meeker David P · CIK 0001385155 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2035-06-10 F1 · derivative.exercise_date: This option was granted on June 11, 2025. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer. Read SEC document
June 03, 2025 Filed Jun 5, 2025 20:16 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	Exercise / conversionStock Option (Right to Buy) · Derivative	43,620	$0.00 Strike: $4.59	$0.00	Disclosure SEC source: 0001104659-25-056838 · tm2517215-1_4seq1.xml · derivative · entry 4 Meeker David P · CIK 0001385155 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 43,620 shares Expires 2025-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option is fully vested. Read SEC document
June 03, 2025 Filed Jun 5, 2025 20:16 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	SaleCommon Stock	274	$65.60	$17,975.14	Disclosure SEC source: 0001104659-25-056838 · tm2517215-1_4seq1.xml · nonDerivative · entry 3 Meeker David P · CIK 0001385155 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 201,825 F2 · kind: The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 plan adopted by the Reporting Person on March 3, 2025. F4 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $65.60 to $65.61 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
June 03, 2025 Filed Jun 5, 2025 20:16 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	SaleCommon Stock	43,346	$65.04	$2,819,358.21	Disclosure SEC source: 0001104659-25-056838 · tm2517215-1_4seq1.xml · nonDerivative · entry 2 Meeker David P · CIK 0001385155 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 202,099 F2 · kind: The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 plan adopted by the Reporting Person on March 3, 2025. F3 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $64.59 to $65.58 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
June 03, 2025 Filed Jun 5, 2025 20:16 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	Exercise / conversionCommon Stock	43,620	$4.59	$200,215.80	Disclosure SEC source: 0001104659-25-056838 · tm2517215-1_4seq1.xml · nonDerivative · entry 1 Meeker David P · CIK 0001385155 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 245,445 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 544 additional shares acquired under the Issuer's Employee Stock Purchase Plan. Read SEC document
February 19, 2025 Filed Feb 20, 2025 02:48 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	SaleCommon Stock	9,896	$57.22	$566,249.12	Disclosure SEC source: 0001104659-25-015322 · tm257103-6_4seq1.xml · nonDerivative · entry 2 Meeker David P · CIK 0001385155 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 201,281 F2 · kind: The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. Read SEC document
February 16, 2025 Filed Feb 20, 2025 02:48 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	Exercise / conversionRestricted Stock Units · Derivative	21,250	$0.00	$0.00	Disclosure SEC source: 0001104659-25-015322 · tm257103-6_4seq1.xml · derivative · entry 5 Meeker David P · CIK 0001385155 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,750 Underlying: Common Stock · 21,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F5 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 16, 2026, February 16, 2027 and February 16, 2028. The restricted stock units have no expiration date. F5 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 16, 2026, February 16, 2027 and February 16, 2028. The restricted stock units have no expiration date. Read SEC document
February 16, 2025 Filed Feb 20, 2025 02:48 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	Exercise / conversionCommon Stock	21,250	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-25-015322 · tm257103-6_4seq1.xml · nonDerivative · entry 1 Meeker David P · CIK 0001385155 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 211,177 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document
February 14, 2025 Filed Feb 20, 2025 02:48 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	GrantStock Options (Right to Buy) · Derivative	200,000	$0.00 Strike: $56.69	$0.00	Disclosure SEC source: 0001104659-25-015322 · tm257103-6_4seq1.xml · derivative · entry 4 Meeker David P · CIK 0001385155 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2035-02-13 F4 · derivative.exercise_date: The stock options were granted on February 14, 2025. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document
February 14, 2025 Filed Feb 20, 2025 02:48 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	GrantRestricted Stock Units · Derivative	133,350	$0.00	$0.00	Disclosure SEC source: 0001104659-25-015322 · tm257103-6_4seq1.xml · derivative · entry 3 Meeker David P · CIK 0001385155 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 133,350 Underlying: Common Stock · 133,350 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 14, 2026, February 14, 2027, February 14, 2028 and February 14, 2029. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 14, 2026, February 14, 2027, February 14, 2028 and February 14, 2029. The restricted stock units have no expiration date. Read SEC document
February 04, 2025 Filed Feb 5, 2025 02:25 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	SaleCommon Stock	4,278	$59.43	$254,241.54	Disclosure SEC source: 0001104659-25-009285 · tm255457-3_4seq1.xml · nonDerivative · entry 2 Meeker David P · CIK 0001385155 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 189,927 F2 · kind: The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. F3 · balance_after: Includes 5,475 additional shares acquired under the Issuer's Employee Stock Purchase Plan. Read SEC document
February 01, 2025 Filed Feb 5, 2025 02:25 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	Exercise / conversionRestricted Stock Units · Derivative	14,125	$0.00	$0.00	Disclosure SEC source: 0001104659-25-009285 · tm255457-3_4seq1.xml · derivative · entry 3 Meeker David P · CIK 0001385155 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,250 Underlying: Common Stock · 14,125 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date. F4 · derivative.expiration_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date. Read SEC document
February 01, 2025 Filed Feb 5, 2025 02:25 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	Exercise / conversionCommon Stock	14,125	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-25-009285 · tm255457-3_4seq1.xml · nonDerivative · entry 1 Meeker David P · CIK 0001385155 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 194,205 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document
August 27, 2024 Filed Aug 29, 2024 20:55 UTC	Trevi Therapeutics, Inc. TRVI · Entity 4387	Exercise / conversionStock Option (right to buy) · Derivative	4,555	$0.00 Strike: $1.43	$0.00	Disclosure SEC source: 0000950170-24-101926 · ownership.xml · derivative · entry 3 Meeker David P · CIK 0001385155 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,555 shares Expires 2024-11-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option was granted on November 25, 2014. The 4,555 shares of common stock underlying the option vested as to 25% of the shares on November 25, 2015 and vested as to the remaining 75% of the shares in equal quarterly installments thereafter through November 25, 2018. Read SEC document
August 27, 2024 Filed Aug 29, 2024 20:55 UTC	Trevi Therapeutics, Inc. TRVI · Entity 4387	SaleCommon Stock	4,555	$2.93	$13,352.53	Disclosure SEC source: 0000950170-24-101926 · ownership.xml · nonDerivative · entry 2 Meeker David P · CIK 0001385155 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 352,489 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.9100 to $2.9500 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
August 27, 2024 Filed Aug 29, 2024 20:55 UTC	Trevi Therapeutics, Inc. TRVI · Entity 4387	Exercise / conversionCommon Stock	4,555	$1.43	$6,513.65	Disclosure SEC source: 0000950170-24-101926 · ownership.xml · nonDerivative · entry 1 Meeker David P · CIK 0001385155 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 357,044 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 13, 2024 Filed Jun 14, 2024 20:30 UTC	Trevi Therapeutics, Inc. TRVI · Entity 4387	GrantNonstatutory Stock Option (right to buy) · Derivative	30,000	$0.00 Strike: $2.77	$0.00	Disclosure SEC source: 0000950170-24-073726 · ownership.xml · derivative · entry 1 Meeker David P · CIK 0001385155 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-06-12 F1 · derivative.exercise_date: This option was granted on June 13, 2024. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer. Read SEC document
March 19, 2024 Filed Mar 20, 2024 00:54 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	SaleCommon Stock	45,494	$39.22	$1,784,274.68	Disclosure SEC source: 0001104659-24-036316 · tm249308-4_4seq1.xml · nonDerivative · entry 1 Meeker David P · CIK 0001385155 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 174,605 F1 · kind: The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $39.04 to $39.22. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
February 16, 2024 Filed Feb 22, 2024 00:03 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	GrantStock Option (Right to Buy) · Derivative	259,000	$0.00 Strike: $49.23	$0.00	Disclosure SEC source: 0001104659-24-026162 · tm246920-7_4seq1.xml · derivative · entry 3 Meeker David P · CIK 0001385155 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 259,000 Underlying: Common Stock · 259,000 shares Expires 2034-02-15 F4 · derivative.exercise_date: The stock options were granted on February 16, 2024. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document
February 16, 2024 Filed Feb 22, 2024 00:03 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	GrantRestricted Stock Units · Derivative	85,000	$0.00	$0.00	Disclosure SEC source: 0001104659-24-026162 · tm246920-7_4seq1.xml · derivative · entry 2 Meeker David P · CIK 0001385155 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 16, 2026, February 16, 2027 and February 16, 2028. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 16, 2026, February 16, 2027 and February 16, 2028. The restricted stock units have no expiration date. Read SEC document
February 16, 2024 Filed Feb 22, 2024 00:03 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	GrantCommon Stock	99,000	$0.00	$0.00	Disclosure SEC source: 0001104659-24-026162 · tm246920-7_4seq1.xml · nonDerivative · entry 1 Meeker David P · CIK 0001385155 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 220,099 F1 · shares: The Issuer previously granted the Reporting Person an award of restricted stock units that vest based on the Issuer's satisfaction of certain performance objectives. On February 16, 2024, the Board determined that the performance condition had been satisfied. Read SEC document
February 01, 2024 Filed Feb 5, 2024 23:53 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	Exercise / conversionRestricted Stock Units · Derivative	14,125	$0.00	$0.00	Disclosure SEC source: 0001104659-24-010797 · tm245251-2_4seq1.xml · derivative · entry 3 Meeker David P · CIK 0001385155 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,375 Underlying: Common Stock · 14,125 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date. Read SEC document
February 01, 2024 Filed Feb 5, 2024 23:53 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	SaleCommon Stock	4,361	$45.06	$196,506.66	Disclosure SEC source: 0001104659-24-010797 · tm245251-2_4seq1.xml · nonDerivative · entry 2 Meeker David P · CIK 0001385155 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,099 F2 · kind: The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. Read SEC document
February 01, 2024 Filed Feb 5, 2024 23:53 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	Exercise / conversionCommon Stock	14,125	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-24-010797 · tm245251-2_4seq1.xml · nonDerivative · entry 1 Meeker David P · CIK 0001385155 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,460 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document
June 28, 2023 Filed Jun 30, 2023 20:00 UTC	Trevi Therapeutics, Inc. TRVI · Entity 4387	GrantNonstatutory Stock Option (right to buy) · Derivative	30,000	$0.00 Strike: $2.27	$0.00	Disclosure SEC source: 0001209191-23-040287 · doc4.xml · derivative · entry 1 Meeker David P · CIK 0001385155 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-06-27 F1 · derivative.exercise_date: This option was granted on June 28, 2023. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer. Read SEC document
February 01, 2023 Filed Feb 3, 2023 21:08 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	GrantStock Option (Right to Buy) · Derivative	229,600	$0.00 Strike: $27.35	$0.00	Disclosure SEC source: 0001104659-23-010490 · tm235340-4_4seq1.xml · derivative · entry 2 Meeker David P · CIK 0001385155 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,600 Underlying: Common Stock · 229,600 shares Expires 2033-01-31 F3 · derivative.exercise_date: The stock options were granted on February 1, 2023. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document
February 01, 2023 Filed Feb 3, 2023 21:08 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	GrantRestricted Stock Units · Derivative	56,500	$0.00	$0.00	Disclosure SEC source: 0001104659-23-010490 · tm235340-4_4seq1.xml · derivative · entry 1 Meeker David P · CIK 0001385155 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,500 Underlying: Common Stock · 56,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date. F2 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date. Read SEC document
June 23, 2022 Filed Jun 23, 2022 20:59 UTC	Trevi Therapeutics, Inc. TRVI · Entity 4387	GrantNonstatutory Stock Option (right to buy) · Derivative	20,000	$0.00 Strike: $2.27	$0.00	Disclosure SEC source: 0001209191-22-038958 · doc4.xml · derivative · entry 1 Meeker David P · CIK 0001385155 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-22 F1 · derivative.exercise_date: This option was granted on June 23, 2022. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer. Read SEC document
June 23, 2022 Filed Jul 1, 2022 20:58 UTC Amendment	Trevi Therapeutics, Inc. TRVI · Entity 4387	GrantNonstatutory Stock Option (right to buy) · Derivative	20,000	$0.00 Strike: $2.27	$0.00	Disclosure SEC source: 0001209191-22-040298 · doc4a.xml · derivative · entry 1 Meeker David P · CIK 0001385155 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-22 F1 · derivative.exercise_date: This option was granted on June 23, 2022. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer. F2 · ownership.direct: This amendment to the Form 4 originally filed for the reporting person on June 23, 2022 is being filed solely to attach the power of attorney exhibit that was inadvertently excluded from the original filing. Read SEC document
February 09, 2022 Filed Feb 12, 2022 02:33 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	GrantStock Option (Right to Buy) · Derivative	510,000	$0.00 Strike: $6.80	$0.00	Disclosure SEC source: 0001104659-22-020892 · tm226394-4_4seq1.xml · derivative · entry 1 Meeker David P · CIK 0001385155 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 510,000 Underlying: Common Stock · 510,000 shares Expires 2032-02-08 F1 · derivative.exercise_date: The stock options were granted on February 9, 2022. The option vests and becomes exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document
June 16, 2021 Filed Jun 17, 2021 20:00 UTC	Trevi Therapeutics, Inc. TRVI · Entity 4387	GrantNonstatutory Stock Option (right to buy) · Derivative	20,000	$0.00 Strike: $2.25	$0.00	Disclosure SEC source: 0001209191-21-041388 · doc4.xml · derivative · entry 1 Meeker David P · CIK 0001385155 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-06-15 F1 · derivative.exercise_date: This option was granted on June 16, 2021. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer. Read SEC document
March 30, 2021 Filed Mar 31, 2021 20:08 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	PurchaseCommon Stock	10,000	$20.17	$201,713.00	Disclosure SEC source: 0001104659-21-044745 · tm2111512-1_4seq1.xml · nonDerivative · entry 1 Meeker David P · CIK 0001385155 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,335 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.03 to $20.22, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
February 11, 2021 Filed Feb 16, 2021 22:26 UTC	RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693	GrantStock Option (right to buy) · Derivative	220,000	$0.00 Strike: $30.66	$0.00	Disclosure SEC source: 0001104659-21-024406 · tm216849-1_4seq1.xml · derivative · entry 1 Meeker David P · CIK 0001385155 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,000 Underlying: Common Stock · 220,000 shares Expires 2031-02-10 F1 · derivative.exercise_date: The stock options were granted on February 11, 2021. The option vests and becomes exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document
November 17, 2020 Filed Nov 20, 2020 01:26 UTC	MyoKardia, Inc. MYOK · Entity 145206	Disposition to issuerStock Option (Right to buy) · Derivative	3,000	Not disclosed Strike: $100.27	Not disclosed	Disclosure SEC source: 0000899243-20-031763 · doc4.xml · derivative · entry 6 Meeker David P · CIK 0001385155 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires not disclosed F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.